Compare Heron Therapeutics Inc (HRTX) vs Payoneer Global Inc (PAYO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Payoneer Global Inc — how do they compare? Heron Therapeutics Inc trades at $0.37 (market cap $68.01M), while Payoneer Global Inc trades at $7.19 (market cap $2.43B). The key difference: Payoneer Global Inc is far larger — about 35.7× Heron Therapeutics Inc's market cap, and Payoneer Global Inc is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and Payoneer Global Inc for 61 Days on average.
| HRTX | PAYO | |
|---|---|---|
Market Cap | $68.01M | $2.43B |
Volume | 1,891,941 | 1,342,701 |
Sector | Health | Technology |
52-Week High | $1.49 | $7.18 |
52-Week Low | $0.27 | $4.27 |
Typical Hold Time | 35 Days | 61 Days |
Enterprise Value | $174.75M | $2.17B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.39, up 17.58% today, with a bullish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7 million but missed EPS estimates with a $0.03 loss. Despite negative profitability metrics, analyst consensus remains strongly positive with 89% buy ratings. Recent news highlights ongoing comparisons with peers and earnings performance discussions.
The outlook is mixed: strong analyst support and technical momentum suggest potential upside, but persistent losses and high valuation ratios pose significant risks. Investment opportunity hinges on revenue growth translating to profitability, while key risks include execution challenges and competitive pressures in the biotechnology sector.
Payoneer (PAYO) trades at $7.16, up 0.14% on the day, with a bullish technical signal from moving averages and a mixed earnings history including a Q2 2026 miss. Revenue grew to $821.16M in 2025, but net income declined to $73.19M, compressing margins. The company renewed its partnership with Etsy through 2029 and faces ongoing legal scrutiny regarding its proposed acquisition by Nuvei.
The outlook is cautious; while analyst consensus is 60% buy-rated and cash flow trends are positive, risks include earnings volatility, acquisition uncertainty, and competitive pressures. Investors should weigh strong institutional interest against execution challenges and margin pressures for medium-term growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Payoneer Global Inc
Payoneer Global Inc is the world's go-to partner for digital commerce, everywhere. The company started as a cross-border payments platform that empowers businesses, online sellers, and freelancers. The platform allows the users to get paid in multiple currencies, bill global clients, and sell on marketplaces worldwide.
Read more on PAYO →
